Literature DB >> 11834332

Impact of duodenal feeding on the oxygen balance of the splanchnic region during different phases of severe burn injury.

Harald Andel1, Matthias Rab, Dorothea Andel, Klaus Horauf, Dagmar Felfernig, Wolfgang Schramm, Michael Zimpfer.   

Abstract

Enteral nutrition is recommended in burned patients. Depending on the amount administered, enteral feeding causes an increase of intestinal oxygen-demand. Since intestinal perfusion is decreased after major burns the aim of this study was to evaluate, whether duodenal feeding might be a cofactor for the development of a splanchnic O(2)-imbalance. In 15 severely burned patients during duodenal feeding starting within 6 h after injury the assessment of the CO(2)-gap between arterial and gastric CO(2), as a parameter for the measurement of intestinal O(2)-balance was performed. Beginning prior to enteral nutrition CO(2)-gap measurements were carried out to show when the CO(2)-gap increased above 30 mmHg during the whole critical illness phase of the patients. When the CO(2)-gap increased above 30 mmHg enteral nutrition was reduced by 50% and the CO(2)-gap was measured 1 h later. In none of the patients the CO(2)-gap increased during increase of enteral nutrition. In seven patients, the CO(2)-gap increased between the 6th and 13th day above 30 mmHg and fell significantly 1 h after reduction of enteral nutrition. Contrary to the early postburn phase, enteral feeding might have adverse effects on the oxygen balance of the intestine in the later stages of the critical illness phase.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11834332     DOI: 10.1016/s0305-4179(01)00059-6

Source DB:  PubMed          Journal:  Burns        ISSN: 0305-4179            Impact factor:   2.744


  1 in total

1.  Post-pyloric enteral nutrition in septic patients: effects on hepato-splanchnic hemodynamics and energy status.

Authors:  Richard Rokyta; Martin Matejovic; Ales Krouzecky; Vaclav Senft; Ladislav Trefil; Ivan Novak
Journal:  Intensive Care Med       Date:  2004-02-06       Impact factor: 17.440

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.